Jone-Long Ko

Title: Innovations of Jone-Long Ko

Introduction

Jone-Long Ko is a prominent inventor based in Cambridge, MA, known for his significant contributions to the field of immunology. He holds a total of five patents, showcasing his innovative work in developing monoclonal antibodies that target specific regions of the T cell antigen receptor.

Latest Patents

His latest patents include groundbreaking inventions related to monoclonal antibodies reactive with defined regions of the T cell antigen receptor (TCR). One of the key inventions provides monoclonal antibodies that recognize a constant region of the alpha chain of the TCR. Specifically, two monoclonal antibodies, termed αF1 and αF2, react with different epitopes on the framework region of the α monomer of the TCR molecule. Additionally, he has developed monoclonal antibodies that target variable regions of the beta chain of the TCR, including W112 and 2D1, which react with β chain variable regions Vβ5.3 and Vβ8.1, respectively. Furthermore, his work includes monoclonal antibody δTCS1, isotype IgG2a, which is reactive with a variable region of the delta chain of the TCR. These monoclonal antibodies have significant value in both diagnosis and therapy, serving as useful tools for studying the immune system.

Career Highlights

Throughout his career, Jone-Long Ko has worked with notable companies such as Astra Ab and T Cell Sciences, Inc. His experience in these organizations has contributed to his expertise in the field of immunology and antibody development.

Collaborations

Some of his notable coworkers include Robert V Skibbens and Larry D Henry, who have collaborated with him on various projects related to his innovative work.

Conclusion

Jone-Long Ko's contributions to the field of immunology through his patents on monoclonal antibodies have made a significant impact on the study and treatment of immune-related conditions. His work continues to influence advancements in medical research and therapy.